ROG logo

Roche Holding AG Stock Price

SWX:ROG Community·CHF 247.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 233 Fair Values set on narratives written by author

ROG Share Price Performance

CHF 288.50
25.10 (9.53%)
4.5% undervalued intrinsic discount
CHF 302.06
Fair Value
CHF 288.50
25.10 (9.53%)
4.5% undervalued intrinsic discount
CHF 302.06
Fair Value
Price CHF 288.50
bazza CHF 302.06
AnalystConsensusTarget CHF 299.75
AnalystLowTarget CHF 230.00

ROG Community Narratives

bazza·
Fair Value CHF 302.06 4.5% undervalued intrinsic discount

Roche Holding will see a 4.2576% revenue growth shaking the market

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AnalystConsensusTarget·
Fair Value CHF 298.64 3.4% undervalued intrinsic discount

Diagnostics, Pipeline And Automation Will Fuel Future Success

1users have liked this narrative
0users have commented on this narrative
136users have followed this narrative
AnalystLowTarget·
Fair Value CHF 230 25.4% overvalued intrinsic discount

Regulatory Scrutiny And Generic Competition Will Erode Pricing Power

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent ROG News & Updates

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Roche Holding AG Key Details

CHF 63.5b

Revenue

CHF 16.0b

Cost of Revenue

CHF 47.5b

Gross Profit

CHF 38.1b

Other Expenses

CHF 9.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
11.09
Gross Margin
74.79%
Net Profit Margin
14.85%
Debt/Equity Ratio
100.0%

Roche Holding AG Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Established dividend payer and good value.

2 Risks
3 Rewards

About ROG

Founded
1896
Employees
103249
CEO
Thomas Schinecker
WebsiteView website
www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Swiss Market Performance

  • 7 Days: 3.1%
  • 3 Months: 3.2%
  • 1 Year: 3.4%
  • Year to Date: 6.2%
The market is up 3.1% over the last week, with the Healthcare sector leading the way, up 6.7%. As for the past 12 months, the market is up 3.4%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›